Publications

  1. Pavelko KD, Bell MP, Karyampudi L, Hansen MJ, Allen KS, Knutson KL, Pease LR. The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine. Mol Ther. 2013 May; 21(5):1087-95. Epub 2013 Apr 09. 2315372
    View PubMed
  2. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2013 Mar 11. [Epub ahead of print] 2309452
    View PubMed
  3. Henle AM, Erskine CL, Benson LM, Clynes R, Knutson KL. Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells. J Immunol. 2013 Jan 1; 190(1):479-88. Epub 2012 Nov 23. 2285809
    View PubMed
  4. Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol. 2013; 33(2):137-64. 2316562
    View PubMed
  5. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med. 2013; 11:20. Epub 2013 Jan 24. 2302528
    View PubMed
  6. Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, Winterhoff B, Phelan CM, Schildkraut JM, Weber RP, Iversen E, Berchuck A, Sutphen R, Birrer Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS One. 2013; 8(1):e53903. Epub 2013 Jan 30. 2301276
    View PubMed
  7. Juskewitch JE, Knudsen BE, Platt JL, Nath KA, Knutson KL, Brunn GJ, Grande JP. LPS-induced murine systemic inflammation is driven by parenchymal cell activation and exclusively predicted by early MCP-1 plasma levels. Am J Pathol. 2012 Jan; 180(1):32-40. Epub 2011 Nov 07. 2204847
    View PubMed
  8. Shire AM, Sandhu DS, Kaiya JK, Oseini AM, Yang JD, Chaiteerakij R, Mettler TA, Giama NH, Roberts RO, Therneau TM, Petersen GM, Knutson KL, Roberts LR. Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. Mayo Clin Proc. 2012 Jan; 87(1):17-24. 2215190
    View PubMed
  9. Juskewitch JE, Platt JL, Knudsen BE, Knutson KL, Brunn GJ, Grande JP. Disparate roles of marrow- and parenchymal cell-derived TLR4 signaling in murine LPS-induced systemic inflammation. Sci Rep. 2012; 2:918. Epub 2012 Dec 04. 2288197
    View PubMed
  10. Davis JM 3rd, Knutson KL, Skinner JA, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis. Arthritis Res Ther. 2012; 14(1):R24. Epub 2012 Jan 31. 2221053
    View PubMed
  11. Erskine CL, Henle AM, Knutson KL. Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system. J Vis Exp. 2012; (66):e3683. Epub 2012 Aug 08. 2264428
    View PubMed
  12. Krause ML, Davis JM 3rd, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis. Clin Immunol. 2011 Oct; 141(1):67-72. Epub 2011 May 30. 2172243
    View PubMed
  13. Erskine CL, Krco CJ, Hedin KE, Borson ND, Kalli KR, Behrens MD, Heman-Ackah SM, von Hofe E, Wettstein PJ, Mohamadzadeh M, Knutson KL. MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells. J Immunol. 2011 Jul 1; 187(1):316-24. Epub 2011 May 25. 2204891
    View PubMed
  14. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 2011 Jul 1; 71(13):4707-19. Epub 2011 May 09. 2163993
    View PubMed
  15. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011 Jun 15; 186(12):6905-13. Epub 2011 May 06. 2163952
    View PubMed
  16. Davis JM 3rd, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Roger VL, Matteson EL, Gabriel SE. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum. 2011 Jun; 63(6):1497-506. 2151730
    View PubMed
  17. White KL, Rider DN, Kalli KR, Knutson KL, Jarvik GP, Goode EL. Genomics of the NF-kappaB signaling pathway: hypothesized role in ovarian cancer. Cancer Causes Control. 2011 May; 22(5):785-801. Epub 2011 Feb 27. 2151551
    View PubMed
  18. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011 Apr; 3(4):539-56. 2157495
    View PubMed
  19. Krause ML, Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. Corrigendum to "Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis" [Clin. Immunol. 141 (2011) 67-72]. Clin Immunol. 2011; 141(3):372. 2211492
  20. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat. 2010 Aug; 123(1):39-49. Epub 2009 Nov 08. 2110503
    View PubMed
  21. Davis JM 3rd, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells. J Immunol. 2010 Jun 15; 184(12):7297-304. Epub 2010 May 21. 2101976
    View PubMed
  22. Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J. transl. med. 2010 Jun 7; 8. 2110500
    View PubMed
  23. Taylor JA, Cummins NW, Bren GD, Rizza SA, Kolbert CP, Behrens MD, Knutson KL, Kahl JC, Asmann YW, Badley AD. Casp8p41 expression in primary T cells induces a proinflammatory response. AIDS. 2010 Jun 1; 24(9):1251-8. 1992862
    View PubMed
  24. Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun; 59(6):943-53. Epub 2010 Feb 06. 1998044
    View PubMed
  25. Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res. 2010 Apr 15; 70(8):3005-8. 1997869
    View PubMed
  26. Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res. 2010 Feb 1; 16(3):825-34. Epub 2010 Jan 26. 1983173
    View PubMed
  27. Karyampudi L, Krco CJ, Kalli KR, Erskine CL, Hartmann LC, Goodman K, Ingle JN, Maurer MJ, Nassar A, Yu C, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunol Immunother. 2010 Jan; 59(1):161-71. Epub 2009 Jul 21. 1953763
    View PubMed
  28. Karyampudi L, Knutson KL. Antibodies in cancer immunotherapy. Cancer Biomark. 2010; 6(5-6):291-305. 2121236
    View PubMed
  29. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009 Oct; 137(4):1270-9. Epub 2009 Jul 03. 1959595
    View PubMed
  30. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009 Apr 1; 69(7):2887-95. Epub 2009 Mar 10. 1931015
    View PubMed
  31. Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, Kamen BA, Low PS, Knutson KL. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One. 2009; 4(7):e6292. Epub 2009 Jul 20. 1953779
    View PubMed
  32. White KL, Vierkant RA, Phelan CM, Fridley BL, Anderson S, Knutson KL, Schildkraut JM, Cunningham JM, Kelemen LE, Pankratz VS, Rider DN, Liebow M, Hartmann LC, Sellers TA, Goode EL. Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer. 2009; 9:170. Epub 2009 Jun 06. 1951164
    View PubMed
  33. Gustafson MP, Knutson KL, Dietz AB. Therapeutic vaccines for malignant brain tumors. Biologics. 2008 Dec; 2(4):753-61. 1897130
  34. Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, Johnson EM, Erskine CL, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Res. 2008 Jun 15; 68(12):4893-901. 1894659
    View PubMed
  35. Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM, Manjili MH. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res. 2008 Apr 1; 68(7):2436-46. 1904800
    View PubMed
  36. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008 Mar; 108(3):619-26. Epub 2008 Jan 28. 1867616
    View PubMed
  37. Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempski J, Gad EA, Disis ML, Knutson KL. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood. 2008 Feb 1; 111(3):1472-9. Epub 2007 Nov 20. 1867784
    View PubMed
  38. Shepard BD, De Forni D, McNamara DR, Foli A, Rizza SA, Abraham RS, Knutson K, Wettstein PJ, Lori F, Badley AD. Beneficial effect of TRAIL on HIV burden, without detectable immune consequences. PLoS One. 2008; 3(8):e3096. Epub 2008 Aug 28. 1915694
    View PubMed
  39. Tracz MJ, Juncos JP, Croatt AJ, Ackerman AW, Grande JP, Knutson KL, Kane GC, Terzic A, Griffin MD, Nath KA. Deficiency of heme oxygenase-1 impairs renal hemodynamics and exaggerates systemic inflammatory responses to renal ischemia. Kidney Int. 2007 Nov; 72(9):1073-80. Epub 2007 Aug 29. 1848882
    View PubMed
  40. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007 Sep 1; 13(17):5133-43. 1841335
    View PubMed
  41. Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol. 2007 Aug; 17(4):275-87. Epub 2007 Jun 26. 1841383
    View PubMed
  42. Tracz MJ, Juncos JP, Grande JP, Croatt AJ, Ackerman AW, Rajagopalan G, Knutson KL, Badley AD, Griffin MD, Alam J, Nath KA. Renal hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in HO-1-/- mice. Am J Pathol. 2007 Jun; 170(6):1820-30. 1828157
    View PubMed
  43. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007 Apr 1; 13(7):2075-81. 1965272
    View PubMed
  44. Radhakrishnan S, Wiehagen KR, Pulko V, Van Keulen V, Faubion WA, Knutson KL, Pease LR. Induction of a Th1 response from Th2-polarized T cells by activated dendritic cells: dependence on TCR:peptide-MHC interaction, ICAM-1, IL-12, and IFN-gamma. J Immunol. 2007 Mar 15; 178(6):3583-92. 1815193
    View PubMed
  45. Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother. 2007 Mar; 56(3):271-85. 1799843
    View PubMed
  46. Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol. 2007 Mar; 37(3):675-85. 1815295
    View PubMed
  47. Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res. 2007 Feb 1; 67(3):1326-34. 1807190
    View PubMed
  48. Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol. 2006 Sep 10; 24(26):4254-61. Epub 2006 Aug 14. 1782497
    View PubMed
  49. Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol. 2006 Aug 1; 177(3):1526-33. 1772871
    View PubMed
  50. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol. 2006 Jul 1; 177(1):84-91. 1769896
    View PubMed
  51. Knutson KL. Strong-arming immune regulation: suppressing regulatory T-cell function to treat cancers. Future Oncol. 2006 Jun; 2(3):379-89. 1782504
    View PubMed
  52. Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL. Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res Treat. 2006 Apr; 96(3):233-41. Epub 2005 Oct 07. 1762819
    View PubMed
  53. Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother. 2006 Jan; 55(1):96-103. Epub 2005 Oct 27. 1740291
    View PubMed
  54. Knutson KL, dela Rosa C, Disis ML. Laboratory analysis of T-cell immunity. Front Biosci. 2006; 11:1932-44. Epub 2006 May 01. 1744082
    View PubMed
  55. Lu H, Knutson KL, Gad E, Disis ML. The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res. 2006; 66(19):9754-61. 1972022
    View PubMed
  56. Knutson KL, Disis ML. Augmenting T helper cell immunity in cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec; 5(4):365-71. 1744064
    View PubMed
  57. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005 Aug; 54(8):721-8. 1718803
    View PubMed
  58. Knutson KL. Cancer vaccines: The next generation. Drug Discovery Today: Therapeutic Strategies. 2005; 2(4):323-30. 1765142
    View PubMed
  59. Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol. 2004 Sep; 24(5):571-8. 1875294
    View PubMed
  60. Knutson KL, Almand B, Dang Y, Disis ML. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 2004 Feb 1; 64(3):1146-51. 1875292
    View PubMed
  61. Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA. Effect of dose on immune response in patients vaccinated with a HER-2/neu intracellular domain protein based vaccine. J Cin Oncol. 200425 2004; 22:1916-1925. 1875293
  62. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Immunology. 2004; 10:942-949. 1875297
  63. Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high affinity binding to multiple class II alleles. Clinical Cancer Research. 2004; 9:5559-55565. 1875290
  64. Knutson KL, Disis ML. IL-12 enhances the generation funciton tumor antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin and Exp Immunol. 2004; 135:322-329. 1875291
  65. Curiel TJ, Wei S, Dong HD, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen LP, Zou WP. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003 May; 9(5):562-7. 1341188
    View PubMed
  66. McNeel DG, Knutson KL, Schiffman K, Davis D, Caron D, Disis ML. Phase I study of an HLA-A2 peptide-based vaccine targeting HER-2/neu in patients with advanced stage prostate cancer. J Clinical Immunology. 2003; 23:62-72. 1875280
  67. Disis ML, Shiota FM, McNeel DG, Knutson KL. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. Immunobiology. 2003; 207(3):179-86. 1875285
    View PubMed
  68. Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellstrom KE, Hellstrom I. Plasmid-based vaccines encoding rat neu and co-stimulatory molecules elicit neu-specific immunity. Mol Ther Cancer. 2003; 2:995-1002. 1875289
  69. Knutson KL, Disis ML. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Hum Immunol. 2002 Jul; 63(7):547-57. 1875279
    View PubMed
  70. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002 Jun 1; 20(11):2624-32. 1875247
    View PubMed
  71. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res. 2002 May; 8(5):1014-8. 1875250
    View PubMed
  72. Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 2002 Apr 15; 99(8):2845-50. 1875244
    View PubMed
  73. Knutson KL, Disis ML. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. Clin Breast Cancer. 2001 Apr; 2(1):73-9. 1875243
    View PubMed
  74. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001 Feb; 107(4):477-84. 1875242
    View PubMed
  75. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat. 2000 Aug; 62(3):245-52. 2269660
    View PubMed
  76. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res. 2000 Apr; 6(4):1347-50. 1875727
    View PubMed
  77. Hmama Z, Nandan D, Sly L, Knutson KL, Herrera-Velit P, Reiner NE. 1alpha,25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J Exp Med. 1999 Dec 6; 190(11):1583-94. 1875238
    View PubMed
  78. Hmama Z, Knutson KL, Herrera-Velit P, Nandan D, Reiner NE. Monocyte adherence induced by lipopolysaccharide involves CD14, LFA-1, and cytohesin-1. Regulation by Rho and phosphatidylinositol 3-kinase. J Biol Chem. 1999 Jan 8; 274(2):1050-7. 2148801
    View PubMed
  79. Knutson KL, Hmama Z, Herrera-Velit P, Rochford R, Reiner NE. Lipoarabinomannan of Mycobacterium tuberculosis promotes protein tyrosine dephosphorylation and inhibition of mitogen-activated protein kinase in human mononuclear phagocytes. Role of the Src homology 2 containing tyrosine phosphatase 1. J Biol Chem. 1998 Jan 2; 273(1):645-52. 1875040
    View PubMed
  80. Herrera-Velit P, Knutson KL, Reiner NE. Phosphatidylinositol 3-kinase-dependent activation of protein kinase C-zeta in bacterial lipopolysaccharide-treated human monocytes. J Biol Chem. 1997 Jun 27; 272(26):16445-52. 1875725
    View PubMed
  81. Knutson KL, Hoenig M. Arachidonic acid-induced down-regulation of protein kinase C delta in beta-cells. J Cell Biochem. 1996 Sep 15; 62(4):543-52. 1874890
    View PubMed
  82. Knutson KL, Hoenig M. Regulation of distinct pools of protein kinase C delta in beta cells. J Cell Biochem. 1996 Jan; 60(1):130-8. 1874889
    View PubMed
  83. Knutson KL, Hoenig M. Identification and subcellular characterization of protein kinase-C isoforms in insulinoma beta-cells and whole islets. Endocrinology. 1994 Sep; 135(3):881-6. 1874876
    View PubMed
  84. Hoenig M, Knutson KL. Effect of protein kinase C on the plasma membrane calcium pump in purified beta cells. Biochemical Medicine and Metabolic Biology. 1994 1994; 53:75-79. 1874887
  85. Zalups RK, Knutson KL, Schnellmann RG. In vitro analysis of the accumulation and toxicity of inorganic mercury in segments of the proximal tubule isolated from the rabbit kidney. Toxicology and Applied Pharmacology 9 1993; 119:221-227. 1874875